A Phase 1/2 interventional study of BMS-986253 and Nivolumab in Cancer and Melanoma, sponsored by Bristol-Myers Squibb. Completed at 72 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Melanoma by Bristol-Myers Squibb — 3 open to participants now, 9 under way, 3 of them phase 3. Melanoma · Bristol-Myers Squibb.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 22nd largest by enrollment of the 75 interventional ones that give a count, is one of 5 that started in 2018, is one of 6 in phase 1/2, and was the 80th registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →3 of the 111 studies in Melanoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Belgium, Canada and 10 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Australia, Canada and 5 more countries
Ages 18+
Bristol-Myers Squibb · Sites in India
Ages 12+
By country, each count listing its studies:
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 33 · Phase 3 23 · Phase 4 1
First in 2002; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 281 is above the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 107 across the 75 interventional studies, 366 across the 32 observational. Of the 90 that completed or were terminated, 41 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Melanoma by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04550247Bristol-Myers SquibbA Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France | 2027-03-15 |
Add it to your calendar (.ics) → With an account.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
This study's enrollment of 281 is above the median of 40 across 2,652 interventional studies indexed under Melanoma.
Browse Melanoma studies →Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Compared within Melanoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986253 · Biological: Nivolumab
Drug: BMS-986253 · Biological: Nivolumab
Drug: BMS-986253 · Biological: Nivolumab · Biological: Ipilimumab
Drug: BMS-986253 · Biological: Nivolumab · Biological: Ipilimumab
Biological: Nivolumab · Biological: Ipilimumab · Other: Placebo
Specified dose on specified days
Specified dose on specified days
Also known as: BMS-936558, Opdivo
Specified dose on specified days
Also known as: BMS-734016, YERVOY
Specified dose on specified days
Number of Participants Experiencing Adverse Events (AEs) - Part 1
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 1.
Time frame: From first dose up to 100 days after last dose (up to 65 months)
Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 1
A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event. This endpoint was prespecified in the protocol to include only participants in Part 1.
Time frame: From first dose up to 100 days after last dose (up to 65 months)
Number of Participants Experiencing Dose Limiting Toxicities (DLTs) - Part 1
Dose-Limiting Toxicities (DLTs) are effects of a treatment that are serious enough to prevent an increase in dose of that treatment, as advised by the Dose Review Team. DLTs will be defined based on the incidence, intensity, and duration of AEs that are possibly related to study treatment. DLTs will include gastrointestinal, hepatic, hematologic, dermatologic, and other AEs. This endpoint was prespecified in the protocol to include only participants in Part 1.
Time frame: From first dose up to 100 days after last dose (up to 65 months)
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 1
Number of participants with any grade adverse events (AEs) leading to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. This endpoint was prespecified in the protocol to include only participants in Part 1.
Time frame: From first dose up to 100 days after last dose (up to 65 months)
Number of Participants Who Died - Part 1
The number of participants who died due to any cause are summarized. This endpoint was prespecified in the protocol to include only participants in Part 1.
Time frame: From first dose up to 100 days after last dose (up to 65 months)
Most Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 1
Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory tests are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 1.
Time frame: From first dose up to 30 days after last dose (up to 63 months)
Objective Response Rate (ORR) - Part 2
Objective Response Rate per blinded independent central review (BICR) is the percentage of participants who have a confirmed complete or partial best overall response (BOR) among participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. This endpoint was prespecified in the protocol to include only participants in Part 2.
Time frame: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 22 months)
Objective Response Rate (ORR) - Part 1
Objective Response Rate per investigator is the percentage of participants who have a confirmed complete or partial best overall response (BOR) among participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. This endpoint was prespecified in the protocol to include only participants in Part 1.
Time frame: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 74 months)
Duration of Response (DOR) - Part 1
DOR for a participant with a best overall response (BOR) of CR or PR is defined as the date of first response up to the date of the first objectively documented tumor progression by the investigator per RECIST v1.1 or death, whichever occurs first. Analysis computed using Kaplan-Meier method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. This endpoint was prespecified in the protocol to include only participants in Part 1.
Time frame: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 74 months)
Maximum Concentration (Cmax) - Part 1
Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and before the administration of a second dose. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Time frame: Cycle 1 Day 1
AUC(0-T)-Area Under Curve From Time Zero up to Last Quantifiable Concentration - Part 1
AUC (0-T) represents the observed exposure to a drug (area under the concentration curve) from first exposure until the last quantifiable concentration. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Time frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Cycle 1 Day 1
AUC(TAU)-Area Under Curve in 1 Dosing Interval - Part 1
Area under the concentration-time curve in 1 dosing interval. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Time frame: Cycle 1 Day 1
Observed Serum Concentration at the End of a Dosing Interval (Ctau) - Part 1
BMS-986253 observed serum concentration at the end of a dosing interval (Ctau). Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except Cycles 1 and 2 (1 cycle=42 days) in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group
Time frame: Cycle 1 Day 1
Total Body Clearance (CLT) - Part 1
Clearance is the rate of elimination of BMS-986253 from the blood calculated as the rate of elimination divided by serum concentration. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Time frame: Cycle 1 Day 1
Average Serum Concentration Over a Dosing Interval (Css-avg) - Part 1
BMS-986253 Average concentration over a dosing interval (\\\[AUC(TAU)/tau\\\] (Css-avg) at steady state. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Time frame: Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1
AUC Accumulation Index (AI_AUC) - Part 1
AUC Accumulation Index is defined as the ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Time frame: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Cmax Accumulation Index (AI_Cmax) - Part 1
BMS-986253 Cmax accumulation index (AI\_Cmax). Ratio of an exposure measure at steady state to that after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Time frame: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Ctau Accumulation Index (AI_Ctau) - Part 1
Ctau is the observed serum concentration at the end of a dosing interval. Ctau accumulation index (AI\_Ctau) is the ratio of an exposure measure at steady state to that after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. Ctau was reported on non-compartmental analysis day, which is on Cycle 1 Day1, Cycle 2 Day 1, Cycle 3 Day 1, or Cycle 4 Day 1 based on data available. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Time frame: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Effective Elimination (T-HALFeff) - Part 1
BMS-986253 effective elimination (T-HALFeff) that explains the degree of accumulation observed for a specific exposure measure. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Time frame: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Time to Maximum Concentration (Tmax) - Part 1
Tmax is defined as the time it takes for a drug to reach the maximum concentration (Cmax) after administration of a drug. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Time frame: Cycle 1 Day 1
Serum Trough Concentration (Ctrough) - Part 1
A serum trough concentration (Ctrough) is the concentration reached by a drug immediately before the next dose is administered. Serum trough concentrations (Ctrough) of BMS-986253 will be summarized with descriptive statistics by treatment and visit. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: The timepoints listed were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Time frame: C1D15, C1D29, C2D1, C2D9, C2D15, C3D1, C4D1, C4D15, C5D1, C7D1, C9D1, C10D1, C14D1, C20D1, and C26D1
Number of Participants With Anti-Drug Antibodies (ADA) - Part 1
Blood samples were evaluated for development of Anti-Drug Antibody (ADA) by a validated electrochemiluminescent (ECL) immunoassay. Baseline is defined as first dose. ADA-positive subject: A subject with at least one ADA positive-sample relative to baseline at any time after initiation of treatment. Persistent Positive (PP): ADA-positive sample at 2 or more consecutive time points, where the first and last ADA-positive samples are at least 16 weeks apart Not PP-Last Sample Positive: Not persistent positive with ADA-positive sample at the last sampling time point Other Positive: Not persistent positive but some ADA-positive samples with the last sample being negative Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected ADA-negative subject: A subject with no ADA-positive sample after the initiation of treatment. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Time frame: C1D1, C1D2, C1D8, C1D15, C1D22, C2D1, C2D2, C2D8, C2D15, C3D1, C4D1, C4D2, C4D8, C4D15, C4D22, C5D1, C9D1, C14D1, C20D1, C26D1, C32D1, C38D1, 30-day follow-up, 100-day follow-up
Change From Baseline in Interleukin 8 (IL-8)- Part 1
Change from baseline in IL-8 measured in pg/mL. Baseline is defined as first dose. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: Some timepoints were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Time frame: C1D2, C1D8, C1D15, C1D22, C1D29, C1D36, C2D1, C2D2, C2D8, C2D15, C2D22, C2D29, C3D1, C3D2, C3D8, C4D1, C4D2, C4D8, C4D15, C4D22, C5D1, C7D1, C8D1, C9D1, C10D1, C11D1, C14D1, C16D1, C17D1, C20D1, C23D1, C26D1, at last dose, and 100 days post last dose
Progression Free Survival (PFS) - Part 2
Progression free survival (PFS) is defined for all randomized participants as the date from randomization to the date of the documentation of disease progression by BICR or death due to any cause, whichever is earlier. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. This endpoint was prespecified in the protocol to include only participants in Part 2.
Time frame: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 22 months)
Number of Participants Experiencing Adverse Events (AEs) - Part 2
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 2.
Time frame: From first dose up to 100 days after last dose (up to 25 months)
Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 2
A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.
Time frame: From first dose up to 100 days after last dose (up to 25 months)
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 2
Number of participants with any grade adverse events (AEs) leading to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time frame: From first dose up to 100 days after last dose (up to 25 months)
Number of Participants Who Died - Part 2
The number of participants who died due to any cause are summarized.
Time frame: From first dose up to 100 days after last dose (up to 25 months)
Most Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 2
Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory tests are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 2.
Time frame: From first dose up to 30 days after last dose (up to 23 months)
| Milestone | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi |
|---|---|---|---|---|---|---|---|---|---|
| Started | 16 | 15 | 18 | 12 | 63 | 20 | 15 | 62 | 60 |
| Randomized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 62 | 60 |
| Completed | 16 | 15 | 18 | 12 | 63 | 20 | 15 | 62 | 57 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: No longer met study criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi |
|---|---|---|---|---|---|---|---|---|---|
| Started | 16 | 15 | 18 | 12 | 63 | 20 | 15 | 62 | 57 |
| Completed | 11 | 10 | 15 | 9 | 51 | 14 | 11 | 58 | 49 |
| Not completed | 5 | 5 | 3 | 3 | 12 | 6 | 4 | 4 | 8 |
| Withdrew: Participant withdrew consent | 2 | 2 | 0 | 0 | 3 | 3 | 1 | 1 | 1 |
| Withdrew: Other reasons | 0 | 1 | 1 | 0 | 3 | 1 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 3 | 1 | 2 | 3 | 6 | 2 | 1 | 3 | 6 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 1.
| Participants | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) - Part 1 | 16 | 14 | 18 | 12 | 60 | 20 | 15 |
A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event. This endpoint was prespecified in the protocol to include only participants in Part 1.
| Participants | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 1 | 13 | 10 | 13 | 7 | 31 | 12 | 9 |
Dose-Limiting Toxicities (DLTs) are effects of a treatment that are serious enough to prevent an increase in dose of that treatment, as advised by the Dose Review Team. DLTs will be defined based on the incidence, intensity, and duration of AEs that are possibly related to study treatment. DLTs will include gastrointestinal, hepatic, hematologic, dermatologic, and other AEs. This endpoint was prespecified in the protocol to include only participants in Part 1.
| Participants | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Dose Limiting Toxicities (DLTs) - Part 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with any grade adverse events (AEs) leading to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. This endpoint was prespecified in the protocol to include only participants in Part 1.
| Participants | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 1 | 3 | 2 | 3 | 3 | 7 | 1 | 3 |
The number of participants who died due to any cause are summarized. This endpoint was prespecified in the protocol to include only participants in Part 1.
| Participants | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Died - Part 1 | 14 | 15 | 17 | 10 | 53 | 13 | 8 |
Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory tests are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 1.
| Participants | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Hemoglobin - Grade 3 | 2 | 1 | 2 | 2 | 7 | 3 | 3 |
| Alanine aminotransferase - Grade 3 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Alkaline phosphatase - Grade 3 | 0 | 0 | 2 | 0 | 2 | 3 | 2 |
| Aspartate aminotransferase - Grade 3 | 0 | 1 | 0 | 0 | 0 | 2 | 1 |
| Phosphate - Grade 3 | 0 | 1 | 2 | 0 | 3 | 1 | 0 |
| Sodium - Grade 3 | 0 | 2 | 1 | 0 | 5 | 1 | 2 |
| Lipase - Grade 3 | 1 | 1 | 2 | 1 | 3 | 0 | 2 |
| Lipase - Grade 4 | 0 | 0 | 0 | 1 | 2 | 0 | 2 |
| Amylase - Grade 3 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Amylase - Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Albumin - Grade 3 | 0 | 0 | 3 | 0 | 2 | 0 | 0 |
Objective Response Rate per investigator is the percentage of participants who have a confirmed complete or partial best overall response (BOR) among participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. This endpoint was prespecified in the protocol to include only participants in Part 1.
| Percentage of Participants | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) - Part 1 | 6.3 (0.2 to 30.2) | 6.7 (0.2 to 31.9) | 16.7 (3.6 to 41.4) | 0 (0.0 to 26.5) | 3.2 (0.4 to 11.0) | 10.0 (1.2 to 31.7) | 13.3 (1.7 to 40.5) |
DOR for a participant with a best overall response (BOR) of CR or PR is defined as the date of first response up to the date of the first objectively documented tumor progression by the investigator per RECIST v1.1 or death, whichever occurs first. Analysis computed using Kaplan-Meier method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. This endpoint was prespecified in the protocol to include only participants in Part 1.
| Months | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) - Part 1 | 3.7 (3.7 to 3.7) | 28.9 (28.9 to 28.9) | 44.6 (8.4 to 44.6) | — | 21.09 (4.0 to 21.1) | 3.4 (3.4 to 3.4) | NA (3.7 to 24.0) |
Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and before the administration of a second dose. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
| ug/mL | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Maximum Concentration (Cmax) - Part 1 | 142.91 ± 52.1 | 352.12 ± 62.7 | 779.90 ± 43.1 | 325.67 ± 24.0 | 919.44 ± 32.8 | 1227.67 ± 23.3 | 999.60 ± 29.4 |
AUC (0-T) represents the observed exposure to a drug (area under the concentration curve) from first exposure until the last quantifiable concentration. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
| h*ug/mL | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| AUC(0-T)-Area Under Curve From Time Zero up to Last Quantifiable Concentration - Part 1 | 19594.22 ± 52.7 | 44821.39 ± 44.5 | 105171.46 ± 29.7 | 42835.41 ± 28.1 | 112123.35 ± 34.2 | 148321.77 ± 32.0 | 118041.10 ± 40.3 |
Area under the concentration-time curve in 1 dosing interval. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
| h*ug/mL | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| AUC(TAU)-Area Under Curve in 1 Dosing Interval - Part 1 | 21301.74 ± 49.5 | 48664.06 ± 42.9 | 106916.11 ± 27.3 | 43844.97 ± 24.8 | 113969.47 ± 30.8 | 153791.84 ± 27.9 | 137809.44 ± 29.5 |
BMS-986253 observed serum concentration at the end of a dosing interval (Ctau). Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except Cycles 1 and 2 (1 cycle=42 days) in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group
| ug/mL | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Observed Serum Concentration at the End of a Dosing Interval (Ctau) - Part 1 | 6.81 ± 173.8 | 14.92 ± 144.4 | 23.68 ± 692.4 | 55.82 ± 53.0 | 141.89 ± 42.6 | 181.84 ± 46.3 | 175.29 ± 46.6 |
Clearance is the rate of elimination of BMS-986253 from the blood calculated as the rate of elimination divided by serum concentration. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
| mL/h | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Total Body Clearance (CLT) - Part 1 | 28.17 ± 49.5 | 24.66 ± 42.9 | 22.45 ± 27.3 | 27.37 ± 24.8 | 21.06 ± 30.8 | 23.41 ± 27.9 | 26.12 ± 29.5 |
BMS-986253 Average concentration over a dosing interval (\\\[AUC(TAU)/tau\\\] (Css-avg) at steady state. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
| ug/mL | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| C2D1 | — | — | — | 182.48 ± 26.6 | 487.85 ± 32.4 | 658.06 ± 26.2 | 397.96 ± 32.7 |
| C3D1 | 59.03 ± 47.1 | 66.87 ± 74.2 | 181.94 ± 19.0 | — | — | — | — |
| C4D1 | — | 115.89 | — | 238.51 ± 20.1 | 535.44 ± 37.4 | 590.45 ± 37.5 | — |
AUC Accumulation Index is defined as the ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
| Ratio | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| C2D1 | — | — | — | 1.45 ± 10.3 | 1.40 ± 22.8 | 1.34 ± 20.6 | 1.19 ± 6.6 |
| C3D1 | 1.47 ± 37.4 | 1.07 ± 16.8 | 1.08 ± 15.7 | — | — | — | — |
| C4D1 | — | 1.30 | — | 1.77 ± 20.0 | 1.64 ± 17.2 | 1.43 ± 7.1 | — |
BMS-986253 Cmax accumulation index (AI\_Cmax). Ratio of an exposure measure at steady state to that after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
| Ratio | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| C2D1 | — | — | — | 1.15 ± 16.7 | 1.11 ± 36.5 | 1.21 ± 18.6 | 1.15 ± 28.3 |
| C3D1 | 0.90 ± 81.6 | 1.05 ± 16.9 | 0.86 ± 35.5 | — | — | — | — |
| C4D1 | 1.58 | 1.19 | — | 1.63 ± 46.0 | 1.36 ± 26.3 | 0.98 ± 30.9 | — |
Ctau is the observed serum concentration at the end of a dosing interval. Ctau accumulation index (AI\_Ctau) is the ratio of an exposure measure at steady state to that after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. Ctau was reported on non-compartmental analysis day, which is on Cycle 1 Day1, Cycle 2 Day 1, Cycle 3 Day 1, or Cycle 4 Day 1 based on data available. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
| Ratio | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| C2D1 | — | — | — | 1.90 ± 22.7 | 1.51 ± 38.0 | 1.39 ± 30.7 | 1.10 ± 21.2 |
| C3D1 | 1.33 ± 91.0 | 1.29 ± 6.5 | 0.90 ± 53.5 | — | — | — | — |
| C4D1 | — | 1.35 | — | 1.97 ± 31.5 | 2.01 ± 35.5 | 1.37 ± 45.2 | — |
BMS-986253 effective elimination (T-HALFeff) that explains the degree of accumulation observed for a specific exposure measure. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
| Hours | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| C2D1 | — | — | — | 200.10 ± 39.12 | 202.89 ± 76.38 | 185.51 ± 71.51 | 145.15 ± 51.41 |
| C3D1 | 410.31 ± 275.42 | 222.95 ± 92.65 | 240.94 ± 92.57 | — | — | — | — |
| C4D1 | — | 317.87 | — | 283.97 ± 84.38 | 247.68 ± 73.44 | 189.42 ± 22.08 | — |
Tmax is defined as the time it takes for a drug to reach the maximum concentration (Cmax) after administration of a drug. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
| Hours | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Time to Maximum Concentration (Tmax) - Part 1 | 3.95 (1.0 to 24.0) | 1.00 (0.9 to 4.1) | 3.81 (2.0 to 6.1) | 4.00 (0.9 to 4.2) | 4.00 (1.0 to 23.5) | 2.18 (1.9 to 21.1) | 1.99 (1.9 to 21.8) |
A serum trough concentration (Ctrough) is the concentration reached by a drug immediately before the next dose is administered. Serum trough concentrations (Ctrough) of BMS-986253 will be summarized with descriptive statistics by treatment and visit. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: The timepoints listed were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
| ng/mL | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| C1D15 - Predose | — | — | — | 59518.0 ± 49.4 | 149309.4 ± 37.0 | 221414.7 ± 26.0 | 166358.6 ± 43.2 |
| C1D29 - Predose | — | — | — | — | — | — | 242843.4 ± 65.2 |
| C2D1 - Predose | 10711.8 ± 124.6 | 14450.3 ± 177.5 | 45153.8 ± 50.4 | 85596.2 ± 38.1 | 187079.9 ± 47.5 | 272401.3 ± 54.1 | 194945.1 ± 35.3 |
| C2D15 - Predose | — | — | — | 98349.7 ± 46.0 | 226385.2 ± 44.5 | 299360.3 ± 44.3 | 112012.1 ± 37.6 |
| C2D29 - Predose | — | — | — | — | — | — | 160198.5 ± 38.2 |
| C3D1 - Predose | 12124.7 ± 82.5 | 21260.6 ± 131.9 | 58149.8 ± 31.5 | 92359.7 ± 35.7 | 224533.3 ± 54.9 | 260971.3 ± 63.9 | 113514.3 ± 12.4 |
| C4D1 - Predose | 27124.2 ± 99.1 | 15763.7 ± 219.2 | 54841.7 ± 43.6 | 86790.7 ± 41.8 | 271535.1 ± 44.9 | 327146.5 ± 55.7 | 145940.5 ± 19.8 |
| C4D15 - Predose | — | — | — | 127803.1 ± 24.5 | 258413.8 ± 48.1 | 356070.0 ± 56.9 | — |
| C5D1 - Predose | — | 34491.0 | — | 125274.8 ± 27.4 | 161340.5 ± 551.8 | 312899.5 ± 65.2 | — |
| C7D1 - Predose | 29506.0 | 51155.0 | 76154.6 ± 26.5 | — | — | — | — |
| C9D1 - Predose | — | — | 48706.0 | 182098.0 ± 43.0 | 263195.0 ± 56.6 | 281410.5 ± 85.2 | — |
| C10D1 - Predose | — | — | 94273.0 | — | — | — | — |
| C14D1 - Predose | — | 95722.0 | 102905.0 | 200795.9 ± 27.5 | 298491.4 ± 50.2 | 361774.6 ± 41.4 | — |
| C20D1 - Predose | — | 72607.0 | 116745.0 | 81342.0 | 424725.7 ± 23.5 | 427000.0 | — |
| C26D1 - Predose | — | 56040.0 | 143209.5 ± 14.8 | — | — | — | — |
Blood samples were evaluated for development of Anti-Drug Antibody (ADA) by a validated electrochemiluminescent (ECL) immunoassay. Baseline is defined as first dose. ADA-positive subject: A subject with at least one ADA positive-sample relative to baseline at any time after initiation of treatment. Persistent Positive (PP): ADA-positive sample at 2 or more consecutive time points, where the first and last ADA-positive samples are at least 16 weeks apart Not PP-Last Sample Positive: Not persistent positive with ADA-positive sample at the last sampling time point Other Positive: Not persistent positive but some ADA-positive samples with the last sample being negative Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected ADA-negative subject: A subject with no ADA-positive sample after the initiation of treatment. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
| Participants | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Baseline ADA positive | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| ADA Positive-Overall | 3 | 2 | 4 | 0 | 2 | 0 | 1 |
| ADA Persistent Positive (PP) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ADA Positive-Not PP last sample positive | 2 | 1 | 1 | 0 | 2 | 0 | 0 |
| ADA Positive-other positive | 1 | 1 | 3 | 0 | 0 | 0 | 1 |
| ADA Negative | 12 | 9 | 12 | 11 | 52 | 15 | 7 |
Change from baseline in IL-8 measured in pg/mL. Baseline is defined as first dose. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days) Note: Some timepoints were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
| pg/mL | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 2 | -96.9 (-891.0 to -24.3) | -37.3 (-105.6 to -7.0) | -66.3 (-377.0 to -5.8) | -48.2 (-115.5 to -21.6) | -48.5 (-141.5 to -4.4) | -82.8 (-509.6 to -8.2) | -76.1 (-268.2 to -18.6) |
| Cycle 1 Day 8 | -78.2 (-857.0 to -5.0) | -31.4 (-94.0 to -6.2) | -58.6 (-350.0 to -4.8) | -40.3 (-107.0 to -17.2) | -69.8 (-1569.6 to 2.2) | -48.1 (-121.0 to -5.0) | -71.9 (-246.0 to -6.0) |
| Cycle 1 Day 15 | -66.2 (-769.0 to 11.0) | -24.4 (-79.0 to 3.0) | -34.3 (-87.0 to -0.3) | -23.6 (-63.0 to -11.0) | -38.0 (-123.2 to 89.0) | -65.8 (-502.5 to -1.0) | -33.5 (-120.0 to -3.0) |
| Cycle 1 Day 22 | -48.0 (-561.0 to 24.0) | 17.4 (-30.8 to 277.0) | -41.6 (-240.0 to 11.8) | -33.0 (-77.0 to -18.6) | -71.3 (-1559.0 to 1.7) | -68.1 (-507.2 to -8.2) | -34.3 (-104.0 to -6.0) |
| Cycle 1 Day 29 | — | — | — | — | — | — | -23.2 (-62.9 to -4.0) |
| Cycle 1 Day 36 | — | — | — | — | — | — | -29.1 (-66.8 to -10.2) |
| Cycle 2 Day 1 | 3.8 (-67.0 to 50.0) | 43.5 (-28.0 to 427.0) | -20.3 (-73.0 to 32.8) | -25.3 (-58.0 to -5.0) | -40.2 (-127.8 to 4.0) | -78.3 (-506.1 to -9.0) | -21.3 (-65.5 to 23.0) |
| Cycle 2 Day 2 | — | — | — | -42.5 (-84.0 to -21.6) | -47.3 (-139.4 to 0.0) | -48.2 (-127.1 to -8.2) | -31.5 (-68.6 to -7.7) |
| Cycle 2 Day 8 | — | — | — | -35.6 (-77.0 to -18.6) | -44.2 (-136.8 to 0.6) | -77.4 (-508.2 to -8.2) | -26.1 (-68.0 to -5.5) |
| Cycle 2 Day 15 | -22.6 (-99.0 to -3.0) | -13.8 (-30.8 to 3.0) | -30.0 (-70.0 to 6.8) | -31.0 (-63.0 to -17.4) | -70.8 (-1569.1 to 3.1) | -74.6 (-501.3 to -7.4) | 9.1 (-22.2 to 56.0) |
| Cycle 2 Day 22 | — | — | — | — | — | — | -18.7 (-29.4 to -2.8) |
| Cycle 2 Day 29 | — | — | — | — | — | — | -22.7 (-26.9 to -18.0) |
| Cycle 3 Day 1 | 2.0 (-82.0 to 44.0) | -4.0 (-25.0 to 30.0) | -16.4 (-49.0 to 21.0) | -25.1 (-38.0 to -8.0) | -86.7 (-1569.6 to 2.3) | -93.5 (-508.2 to -8.1) | -14.4 (-21.0 to 4.0) |
| Cycle 3 Day 2 | — | — | — | — | -24.9 (-24.9 to -24.9) | — | — |
| Cycle 3 Day 8 | -36.3 (-113.0 to -7.0) | -24.5 (-34.5 to -15.0) | -37.0 (-77.0 to -13.2) | — | — | — | — |
| Cycle 3 Day 15 | -44.3 (-117.0 to -2.0) | -20.8 (-31.7 to -14.0) | -24.3 (-46.8 to -5.0) | — | — | — | — |
| Cycle 3 Day 22 | -53.5 (-107.0 to 0.0) | -15.4 (-27.0 to -2.0) | -16.9 (-43.0 to 23.0) | — | — | — | — |
| Cycle 4 Day 1 | -30.3 (-101.0 to 18.0) | -8.8 (-26.0 to 13.0) | -15.5 (-28.4 to 3.5) | -18.5 (-38.9 to 1.0) | -102.9 (-1568.8 to 2.0) | -29.6 (-86.0 to 9.0) | -23.8 (-26.4 to -21.1) |
| Cycle 4 Day 2 | — | -35.7 (-35.7 to -35.7) | — | -32.0 (-41.7 to -21.3) | -33.5 (-81.6 to 0.5) | -44.0 (-96.9 to -13.6) | — |
| Cycle 4 Day 8 | — | -32.1 (-32.1 to -32.1) | — | -30.3 (-40.9 to -19.6) | -32.7 (-81.6 to 3.8) | -43.8 (-92.1 to -8.2) | — |
| Cycle 4 Day 15 | — | -29.0 (-29.0 to -29.0) | — | -26.7 (-38.6 to -17.6) | -34.5 (-122.5 to 6.0) | -46.4 (-90.6 to -8.2) | — |
| Cycle 4 Day 22 | — | -26.0 (-26.0 to -26.0) | — | -28.8 (-38.5 to -19.1) | -30.6 (-81.1 to 2.7) | -43.8 (-94.5 to -7.6) | — |
| Cycle 5 Day 1 | 38.0 (38.0 to 38.0) | — | — | -27.3 (-36.0 to -17.7) | -28.2 (-80.3 to 4.9) | -46.8 (-91.7 to -8.2) | — |
| Cycle 7 Day 1 | -111.0 (-111.0 to -111.0) | -8.0 (-25.0 to 9.0) | -14.6 (-29.7 to -1.7) | -29.3 (-38.5 to -20.0) | -33.0 (-80.8 to -13.6) | -36.9 (-86.6 to -8.2) | — |
| Cycle 8 Day 1 | — | — | -21.8 (-21.8 to -21.8) | — | — | — | — |
| Cycle 9 Day 1 | — | — | -17.0 (-17.0 to -17.0) | -28.2 (-38.5 to -18.6) | -27.8 (-48.3 to -13.6) | -9.1 (-11.0 to -7.1) | — |
| Cycle 10 Day 1 | — | — | -14.2 (-32.3 to 0.7) | — | — | — | — |
| Cycle 11 Day 1 | — | -16.0 (-28.0 to -4.0) | — | -30.7 (-37.7 to -21.4) | -24.4 (-39.5 to -13.6) | -7.6 (-7.6 to -7.6) | — |
| Cycle 14 Day 1 | — | -16.1 (-36.2 to 4.0) | -2.2 (-2.2 to -2.2) | -1.6 (-36.8 to 48.0) | -22.2 (-38.2 to -13.6) | — | — |
| Cycle 16 Day 1 | — | — | -1.6 (-1.6 to -1.6) | — | — | — | — |
| Cycle 17 Day 1 | — | -32.2 (-32.2 to -32.2) | -17.3 (-30.5 to -4.1) | -38.0 (-38.0 to -38.0) | -14.2 (-14.8 to -13.6) | — | — |
| Cycle 20 Day 1 | — | -30.7 (-30.7 to -30.7) | -32.5 (-32.5 to -32.5) | -34.4 (-34.4 to -34.4) | -17.1 (-23.6 to -13.6) | — | — |
| Cycle 23 Day 1 | — | -28.9 (-28.9 to -28.9) | -27.1 (-32.2 to -22.0) | — | -22.6 (-22.6 to -22.6) | — | — |
| Cycle 26 Day 1 | — | -30.8 (-30.8 to -30.8) | -10.0 (-22.6 to 2.5) | — | — | — | — |
| End of Treatment | -44.0 (-105.0 to 17.0) | — | -49.5 (-66.0 to -29.0) | -24.6 (-37.0 to -10.0) | -34.5 (-125.0 to 20.0) | -149.1 (-503.2 to -16.0) | -50.9 (-65.0 to -36.8) |
| Follow-up 1 | — | — | 17.5 (9.0 to 26.0) | — | — | — | — |
Objective Response Rate per blinded independent central review (BICR) is the percentage of participants who have a confirmed complete or partial best overall response (BOR) among participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. This endpoint was prespecified in the protocol to include only participants in Part 2.
| Percentage of Participants | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi |
|---|---|---|
| Objective Response Rate (ORR) - Part 2 | 14.5 (6.9 to 25.8) | 11.7 (4.8 to 22.6) |
Progression free survival (PFS) is defined for all randomized participants as the date from randomization to the date of the documentation of disease progression by BICR or death due to any cause, whichever is earlier. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. This endpoint was prespecified in the protocol to include only participants in Part 2.
| Months | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi |
|---|---|---|
| Progression Free Survival (PFS) - Part 2 | 2.103 (1.873 to 3.778) | 3.318 (1.906 to 3.745) |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 2.
| Participants | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi |
|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) - Part 2 | 62 | 56 |
A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.
| Participants | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi |
|---|---|---|
| Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 2 | 44 | 42 |
Number of participants with any grade adverse events (AEs) leading to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
| Participants | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi |
|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 2 | 16 | 23 |
The number of participants who died due to any cause are summarized.
| Participants | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi |
|---|---|---|
| Number of Participants Who Died - Part 2 | 30 | 17 |
Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory tests are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 2.
| Participants | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi |
|---|---|---|
| Alanine aminotransferase - Grade 3 | 4 | 6 |
| Alanine aminotransferase - Grade 4 | 2 | 1 |
| Aspartate aminotransferase - Grade 3 | 3 | 3 |
| Aspartate aminotransferase - Grade 4 | 1 | 0 |
| Phosphate - Grade 3 | 3 | 3 |
| Sodium - Grade 3 | 6 | 8 |
| Sodium - Grade 4 | 2 | 0 |
| Lipase - Grade 3 | 4 | 5 |
| Lipase - Grade 4 | 5 | 5 |
| Amylase - Grade 3 | 3 | 4 |
Collected over Participants were assessed for all-cause mortality from their first dose to their study completion (up to approximately 74 months). SAEs and Other AEs were assessed from first dose to 100 days post the last dose (up to approximately 65 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: 600 Q4W | 14/16 (87.5%) | 13/16 (81.3%) | 16/16 (100%) |
| Part 1: 1200 Q4W | 15/15 (100%) | 10/15 (66.7%) | 14/15 (93.3%) |
| Part 1: 2400 Q4W | 17/18 (94.4%) | 13/18 (72.2%) | 18/18 (100%) |
| Part 1: 1200 Q2W | 10/12 (83.3%) | 7/12 (58.3%) | 11/12 (91.7%) |
| Part 1: 2400 Q2W | 53/63 (84.1%) | 31/63 (49.2%) | 59/63 (93.7%) |
| Part 1: 3600 Q2W | 13/20 (65%) | 12/20 (60%) | 19/20 (95%) |
| Part 1: 3600Q2W + Nivo + Ipi | 8/15 (53.3%) | 9/15 (60%) | 15/15 (100%) |
| Part 2 Arm A: BMS+Nivo+Ipi | 30/62 (48.4%) | 44/62 (71%) | 61/62 (98.4%) |
| Part 2 Arm B: Placebo+Nivo+Ipi | 17/60 (28.3%) | 42/57 (73.7%) | 54/57 (94.7%) |
| Event | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi |
|---|---|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/16 | 4/15 | 8/18 | 5/12 | 17/63 | 6/20 | 4/15 | 6/62 | 10/57 |
| DysphagiaGastrointestinal disorders | 0/16 | 2/15 | 0/18 | 0/12 | 0/63 | 0/20 | 0/15 | 0/62 | 0/57 |
| PyrexiaGeneral disorders | 0/16 | 0/15 | 0/18 | 0/12 | 0/63 | 0/20 | 2/15 | 2/62 | 3/57 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/16 | 1/15 | 1/18 | 0/12 | 4/63 | 0/20 | 1/15 | 1/62 | 2/57 |
| ColitisGastrointestinal disorders | 0/16 | 0/15 | 1/18 | 0/12 | 0/63 | 0/20 | 1/15 | 4/62 | 7/57 |
| PneumoniaInfections and infestations | 1/16 | 1/15 | 2/18 | 1/12 | 6/63 | 1/20 | 0/15 | 0/62 | 3/57 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/16 | 0/15 | 2/18 | 0/12 | 2/63 | 0/20 | 0/15 | 0/62 | 0/57 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/16 | 0/15 | 2/18 | 0/12 | 0/63 | 0/20 | 0/15 | 0/62 | 0/57 |
| General physical health deteriorationGeneral disorders | 0/16 | 0/15 | 0/18 | 0/12 | 2/63 | 2/20 | 0/15 | 2/62 | 1/57 |
| Large intestinal obstructionGastrointestinal disorders | 0/16 | 0/15 | 0/18 | 1/12 | 0/63 | 0/20 | 0/15 | 0/62 | 0/57 |
| Event | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi |
|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 6/16 | 6/15 | 6/18 | 3/12 | 23/63 | 9/20 | 3/15 | 15/62 | 22/57 |
| DiarrhoeaGastrointestinal disorders | 1/16 | 3/15 | 2/18 | 2/12 | 14/63 | 6/20 | 5/15 | 27/62 | 25/57 |
| AnaemiaBlood and lymphatic system disorders | 3/16 | 2/15 | 5/18 | 2/12 | 16/63 | 7/20 | 6/15 | 21/62 | 14/57 |
| PyrexiaGeneral disorders | 1/16 | 2/15 | 3/18 | 1/12 | 11/63 | 5/20 | 2/15 | 22/62 | 16/57 |
| ConstipationGastrointestinal disorders | 3/16 | 5/15 | 4/18 | 1/12 | 9/63 | 5/20 | 1/15 | 13/62 | 12/57 |
| NauseaGastrointestinal disorders | 3/16 | 5/15 | 4/18 | 4/12 | 15/63 | 5/20 | 3/15 | 20/62 | 18/57 |
| Decreased appetiteMetabolism and nutrition disorders | 5/16 | 0/15 | 4/18 | 0/12 | 21/63 | 3/20 | 4/15 | 12/62 | 12/57 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/16 | 5/15 | 3/18 | 3/12 | 9/63 | 1/20 | 2/15 | 9/62 | 6/57 |
| PruritusSkin and subcutaneous tissue disorders | 0/16 | 1/15 | 0/18 | 1/12 | 12/63 | 2/20 | 1/15 | 18/62 | 18/57 |
| AstheniaGeneral disorders | 2/16 | 2/15 | 0/18 | 2/12 | 9/63 | 3/20 | 2/15 | 18/62 | 5/57 |
All treated participants for Part 1 and all randomized participants for Part 2. Participants in Part 1 were not randomized.
| Age, Continuous(Years) | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 60.4 (35.0 to 86.0) | 64.6 (49.0 to 83.0) | 66.3 (40.0 to 82.0) | 64.4 (51.0 to 87.0) | 63.0 (43.0 to 86.0) | 62.6 (36.0 to 78.0) | 56.6 (32.0 to 79.0) | 62.3 (22.0 to 89.0) | 60.6 (22.0 to 83.0) | 62.2 (22.0 to 89.0) |
| Sex: Female, Male(Participants) | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 4 | 5 | 5 | 18 | 7 | 5 | 22 | 17 | 88 |
| Male | 11 | 11 | 13 | 7 | 45 | 13 | 10 | 40 | 43 | 193 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 1 | 0 | 4 | 0 | 0 | 0 | 1 | 8 |
| Not Hispanic or Latino | 16 | 13 | 17 | 9 | 40 | 13 | 10 | 42 | 41 | 201 |
| Unknown or Not Reported | 0 | 0 | 0 | 3 | 19 | 7 | 5 | 20 | 18 | 72 |
| Race (NIH/OMB)(Participants) | Part 1: 600 Q4W | Part 1: 1200 Q4W | Part 1: 2400 Q4W | Part 1: 1200 Q2W | Part 1: 2400 Q2W | Part 1: 3600 Q2W | Part 1: 3600Q2W + Nivo + Ipi | Part 2 Arm A: BMS+Nivo+Ipi | Part 2 Arm B: Placebo+Nivo+Ipi | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 7 |
| White | 15 | 13 | 18 | 11 | 59 | 18 | 13 | 56 | 53 | 256 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 6 | 6 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2018 to primary completion in Apr 2024, 74 months.
Results were first posted in Jun 2025, 1 year 1 month after primary completion.
Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's 74 months is above that.
Counting every sponsor, half of 220 studies reached it within 60 months; a quarter within 42 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HuMax-IL8